Switch theme
Sign up to access all valuation multiples
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
1998
2.2K+
LTM Revenue $695M
LTM EBITDA $45.8M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NeoGenomics has a last 12-month revenue (LTM) of $695M and a last 12-month EBITDA of $45.8M.
In the most recent fiscal year, NeoGenomics achieved revenue of $661M and an EBITDA of -$1.5M.
NeoGenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeoGenomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $695M | XXX | $661M | XXX | XXX | XXX |
| Gross Profit | $313M | XXX | $290M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $45.8M | XXX | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 0% | XXX | XXX | XXX |
| EBIT | -$91.1M | XXX | -$85.4M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -13% | XXX | XXX | XXX |
| Net Profit | -$79.9M | XXX | -$78.7M | XXX | XXX | XXX |
| Net Margin | -11% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $174M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NeoGenomics's stock price is $7.
NeoGenomics has current market cap of $934M, and EV of $1.2B.
See NeoGenomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $934M | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NeoGenomics has market cap of $934M and EV of $1.2B.
NeoGenomics's trades at 1.8x EV/Revenue multiple, and -781.6x EV/EBITDA.
Equity research analysts estimate NeoGenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeoGenomics has a P/E ratio of -11.7x.
See valuation multiples for NeoGenomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $934M | XXX | $934M | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 25.8x | XXX | -781.6x | XXX | XXX | XXX |
| EV/EBIT | -13.0x | XXX | -13.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.7x | XXX | -11.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -34.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeoGenomics's last 12 month revenue growth is 12%
NeoGenomics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
NeoGenomics's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeoGenomics's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NeoGenomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeoGenomics acquired XXX companies to date.
Last acquisition by NeoGenomics was XXXXXXXX, XXXXX XXXXX XXXXXX . NeoGenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NeoGenomics founded? | NeoGenomics was founded in 1998. |
| Where is NeoGenomics headquartered? | NeoGenomics is headquartered in United States of America. |
| How many employees does NeoGenomics have? | As of today, NeoGenomics has 2.2K+ employees. |
| Who is the CEO of NeoGenomics? | NeoGenomics's CEO is Mr. Anthony P. Zook. |
| Is NeoGenomics publicy listed? | Yes, NeoGenomics is a public company listed on NAS. |
| What is the stock symbol of NeoGenomics? | NeoGenomics trades under NEO ticker. |
| When did NeoGenomics go public? | NeoGenomics went public in 1996. |
| Who are competitors of NeoGenomics? | Similar companies to NeoGenomics include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of NeoGenomics? | NeoGenomics's current market cap is $934M |
| What is the current revenue of NeoGenomics? | NeoGenomics's last 12 months revenue is $695M. |
| What is the current revenue growth of NeoGenomics? | NeoGenomics revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of NeoGenomics? | Current revenue multiple of NeoGenomics is 1.7x. |
| Is NeoGenomics profitable? | Yes, NeoGenomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NeoGenomics? | NeoGenomics's last 12 months EBITDA is $45.8M. |
| What is NeoGenomics's EBITDA margin? | NeoGenomics's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of NeoGenomics? | Current EBITDA multiple of NeoGenomics is 25.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
